Announcements A Joint Statement on Technical, legal, ethical and implementation concerns regarding Aarogya Setu and other apps introduced during COVID-19 in India by Jan Swasthya Abhiyan (JSA), Internet Freedom Foundation (IFF), Forum for Medical Ethics Society (FMES), and All India People’s Science Network (AIPSN)   |   Submission to the National Human Rights Commission (NHRC) on behalf of Hub5 (HEaL Institute, APU, Seher-CHSJ, and IAPH) – COPASAH on human rights issues confronted by ASHAS and ANMs during the Covid-19 pandemic | Aug 7, 2020   |   Letter to MMC by FMES, PUCL-MH, FAOW, and MFC urging to restore its order suspending licenses of two doctors accused of abetting the suicide of Dr Payal Tadvi

Ethics of “standard care” in randomised trials of screening for cervical cancer should not ignore scientific evidence and ground realities

C S Pramesh, Surendra Shastri, Indraneel Mittra, Rajendra A Badwe

DOI: 10.20529/IJME.2013.074


We read with interest the recent editorial  in the IJME on the ethics of standard care in screening trials for cervical cancer in India. The author takes exception to the fact that three cervical cancer screening studies in India used no screening as the control arm, in spite of evidence that the Pap smear is an effective screening tool. The author argues that the Pap smear should have been the standard arm in these trials, and that it was unethical to “withhold” this screening method from participants in the control arm of the trial. At the outset, we wish to declare a conflict of interest in our response by virtue of being investigators of one of the aforesaid trials, but feel it necessary to clarify certain facts that have been overlooked

Full Text





There are currently no refbacks.

Article Views

PDF Downloads

Click here to support US